DW-MRI-Guided Dose Escalation Improves Local Control of Locally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
Open Access
- 1 May 2020
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 3107-3116
Abstract
Background: Nasopharyngeal carcinoma (NPC) is one of the most highly radiosensitive malignancies; however, some locally advanced NPC patients experienced local recurrence even though they received aggressive treatment regimens. Defining the tumor volume precisely is important to escalate the total dose required for the primary tumor. In this study, we aimed to investigate the feasibility and efficacy of dose escalation guided by DW-MRI in patients with locally advanced NPC. Patients and Methods: A total of 230 patients with locally advanced NPC treated with intensive modulated radiotherapy (IMRT) at Sichuan Cancer Hospital between January 2010 and January 2015 were enrolled in this retrospective study. All the patients were treated with all-course of simultaneous integrated boost-IMRT. DW-MRI-guided dose escalation with 2.2– 2.5 Gy/F, qd for 1– 3 days or 1.2– 1.5 Gy/F, bid for 1– 3 days were prescribed to 123 patients. Survival and complication of the patients were evaluated, and multivariate analysis was performed. Results: The median follow-up of patients in the DW-MRI-guided dose-escalation group and the conventional group was 48 months (range 8– 88 months) and 52 months (range 6– 90 months), respectively. The 5-year overall survival rate, distant metastasis-free survival rate, progression-free survival, and local recurrence-free survival (LRFS) of patients in the dose-escalation group and the conventional group were 88% vs 82.5% (p = 0.244), 86.1% vs 83.3% (p = 0.741), 82.2% vs 76.6% (p = 0.286), and 89.1% vs 80.1% (p = 0.029), respectively. Multivariate analysis showed that dose escalation was independent prognostic factor for LRFS (HR 0.386, 95% CI 0.163– 0.909, p = 0.03). Conclusion: DW-MRI-guided dose escalation is a feasible strategy to improve local control of patients with locally advanced NPC. The treatment-related complications are tolerable.Keywords
This publication has 23 references indexed in Scilit:
- Prognostic variables for temporal lobe injury after intensity modulated‐radiotherapy of nasopharyngeal carcinomaCancer Medicine, 2018
- Nasopharyngeal carcinoma incidence and mortality in China, 2013Chinese Journal of Cancer, 2017
- 18F‐Fluoromisonidazole positron emission tomography/CT‐guided volumetric‐modulated arc therapy‐based dose escalation for hypoxic subvolume in nasopharyngeal carcinomas: A feasibility studyHead & Neck, 2017
- A Randomized Pilot Trial Comparing Position Emission Tomography (PET)-Guided Dose Escalation Radiotherapy to Conventional Radiotherapy in Chemoradiotherapy Treatment of Locally Advanced Nasopharyngeal CarcinomaPLOS ONE, 2015
- Preliminary results of trial NPC‐0501 evaluating the therapeutic gain by changing from concurrent‐adjuvant to induction‐concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinomaCancer, 2014
- Diffusion-weighted magnetic resonance imaging for early response assessment of chemoradiotherapy in patients with nasopharyngeal carcinomaMagnetic Resonance Imaging, 2014
- Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapyCancer, 2010
- Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Radiosurgery for skull base malignancies and nasopharyngeal carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997